MicroPort<sup>®</sup> EP Attends the 8th Atrial Fibrillation Key Technology International Forum

Beijing, China - Shanghai MicroPort EP MedTech Co ("MicroPort® EP") recently attended the 8th Atrial Fibrillation Key Technology International Forum held from January 29 to January 30 in Beijing. Hosted by Chinese Heart Rhythm Society and Beijing Lisheng Cardiovascular Health Foundation, the forum provided a platform for domestic and international electrophysiologists to discuss the latest developments of technologies and methods used in ablation procedure.
In the forum, MicroPort® EP displayed several electrophysiological devices including Columbus® 3D EP Navigation System ("Columbus®"), FireMagic® Cool 3D Irrigated Ablation Catheter ("FireMagic® Cool 3D") and EasyLoop™ Circular Mapping Catheter.
 
As the first domestically made 3D EP navigation system with electromagnetic device tracking and full catheter curve display, Columbus® attracted wide attention from experts in attendance. Professor Yansheng Ding of Peking University First Hospital, Professor Changsheng Ma of Beijing Anzhen Hospital of Capital Medical University and Professor Heng Cai of Tianjin Medical University General Hospital visited MicroPort® EP booth to try the devices and spoke highly of the performances of Columbus® and FireMagic® Cool 3D.
 
Columbus® is the first domestically developed 3D EP navigation system that features real time electromagnetic device tracking with cardiac motion compensation and accurate geometric reconstruction of intra cardiac chambers; and FireMagic® Cool 3D helps physicians effectively maneuver the ablation catheter in the body during procedures by providing precise location of the catheter curve in the body and collecting cardiac ECG signals. The use of Columbus® combined with FireMagic® Cool 3D provides physicians with a comprehensive solution for the diagnosis and treatment of complex arrhythmias.
 
Columbus® was granted CE approval in 2013 and is the only domestically made 3D EP navigation system with the CE certificate. In 2015, it was granted Green Channel status to fast track for China Food and Drug Administration ("CFDA") approval, which will significantly shorten the approval period to benefit more Chinese patients earlier than expected.